MRNA•Moderna raised its 2026 revenue growth outlook to 15%-25%, from up to 10% versus 2025, and now expects year-end cash and investments of about $8.1 billion to $8.3 billion. Third-quarter revenue rose 29% to $1.3 billion as the business turned a profit.
Moderna raised its 2026 revenue growth forecast to 15%-25% from up to 10% versus 2025. It expects year-end cash and investments of approximately $8.1 billion to $8.3 billion, compared with its previous forecast of $4.7 billion to $5.2 billion; the higher outlook reflects operational execution and proceeds from a $3 billion convertible notes financing. Third-quarter revenue rose 29% to $1.3 billion, the business turned a profit, and quarterly cash costs fell 10% to $1 billion. Full-year costs are now expected to be lower than previously forecast.
